General Dermatology

William Posten, MD, provides an overview of postoperative radiation therapy as a treatment for keloids, including dosing parameters, safety considerations, and insurance reimbursement trends.

More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.

Findings support ongoing pharmacovigilance monitoring of GLP-1 receptor agonists for hair loss, particularly as semaglutide and tirzepatide use continues to expand.

The priority review pathway cuts the standard 300-day Canadian review timeline to approximately 180 days, reflecting Health Canada's assessment of serious unmet need in the EB population.

In clinical medicine and science, robust often fails because it lacks quantifiable meaning.

William Posten, MD, discusses outcomes, recurrence rates, and the importance of patient adherence in a combined surgical excision and radiation therapy protocol for keloids.

The June issue of Dermatology Times highlights the latest advances in skin cancer, psoriasis, atopic dermatitis, hidradenitis suppurativa, and emerging dermatology technologies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

Phase 1/2 data from RESET-Myositis, RESET-SSc, and RESET-SLE presented at EULAR 2026 show durable immunomodulator-free responses and a consistent safety profile across indications.

Patients experiencing hormonal skin changes frequently report feeling unheard, and Doral Fredericks, PharmD, MBA, argues that active reassessment rather than attribution to aging is the clinical default that's needed.

Experts recommend routine genital assessment as part of comprehensive skin exams rather than relying on patient-initiated reporting of this sensitive manifestation.

Organon's Doral Fredericks, PharmD, MBA, explains why pregnancy and menopause remain chronically understudied in dermatology research and what clinicians are missing as a result.

Discover how oral GliSODin delivers SOD to boost skin defense, enhance retinoids, and reduce UV damage and dark spots—backed by clinical trials.

William Posten, MD, discusses the evolution of keloid treatment and the clinical outcomes he has observed with excision followed by immediate radiation therapy.

Unlike approved AD biologics and JAK inhibitors targeting specific cytokine pathways, GX-03 is designed to modulate inflammatory signaling locally within the skin microenvironment.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

Can misting hypochlorous acid every day improve skin, or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.

Learn more about the in-depth topics covered in the May 2026 print issue of Dermatology Times.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of May.

A review in JEADV Clinical Practice argues that deliberate nail examination in children can generate and narrow a differential diagnosis across virtually every organ system.

At 6-month follow-up, no behavioral outcomes — including sunscreen use, hat use, or reapplication — showed statistically significant improvement over baseline levels.

Apogee plans to initiate 3 phase 3 trials of zumilokibart in moderate to severe atopic dermatitis—ADventure 1, ADventure 2, and ADventure TCS—in the second half of 2026.